Cisplatin Neurotoxicity
- 11 January 1990
- journal article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 322 (2), 126-127
- https://doi.org/10.1056/nejm199001113220210
Abstract
Cisplatin is a chemotherapeutic agent that has dramatically altered the prognosis for patients with a variety of tumors. Its promise as an anticancer agent was recognized in the mid-1960s when Rosenberg et al.1 were studying the effects of electric fields on cellular growth. They noted that Escherichia coli grown in an apparatus containing platinum electrodes elongated but did not divide. This effect was found to be due to the production of cis-diamminedichloroplatinum, now commonly known as cisplatin, in the growth medium. In 1968, as the result of a leap of faith or intuition, investigators began to test cisplatin and . . .Keywords
This publication has 10 references indexed in Scilit:
- Prevention of Cisplatin Neurotoxicity with an ACTH(4–9) Analogue in Patients with Ovarian CancerThe New England Journal of Medicine, 1990
- Dose‐dependent expression of neuronopathy after experimental pyridoxine intoxicationNeurology, 1989
- Longitudinal studies of the neurobiology of vitamin E and other antioxidant systems, and neurological function in the vitamin E deficient ratJournal of the Neurological Sciences, 1988
- Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721Cancer, 1988
- Unusual presentation of cis‐platinum NeuropathyNeurology, 1988
- Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studiesCancer, 1984
- Peripheral sensory neuropathy and cisplatin chemotherapyNeurology, 1984
- cis-Platinum-induced hypomagnesemia and peripheral neuropathyGynecologic Oncology, 1983
- High dose Cis-platinum diammine dichloride.Amelioration of renal toxicity by mannitol diuresisCancer, 1977
- Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum ElectrodeNature, 1965